Nuvaxovid® (COVID-19 vaccine, adjuvanted) – New vaccine approval
May 19, 2025 - Novavax announced the FDA approval of Nuvaxovid (COVID-19 vaccine, adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older. Nuvaxovid is also indicated for individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Top